VERACYTE, INC.
In the published model solve dated 2026-Q2, anchored at $46.09, VERACYTE, INC. (VCYT) is priced for today's economics sustained for ~17.5 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 25, 2026 from SEC EDGAR filings.
• Among the diagnostics companies it is measured against, this is the only one earning an operating profit, at 8.4% of revenue on a trailing basis, while NTRA runs at minus 13.0% and GH at minus 41.4%. • The business is not the problem; the price is. It stands at roughly 99 times what the company earned in operating profit last year, a level no standard valuation approach comes close to reaching. • Second-quarter results are due July 30, 2026, the next check on whether Decipher Prostate and Afir
Is VCYT overvalued? See what's priced in →
325 institutional managers reported holding VCYT in 13F filings for the quarter ended 2026-03-31. 40 opened new positions that quarter. Held by BlackRock, Vanguard Group, FMR (Fidelity), among others. On the short side, 8.5M shares were sold short as of the 2026-06-15 count, about 10% of shares outstanding (6.5 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
VCYT's share count grew 18.2% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at VCYT over the trailing three years. Absence is a fact about the company, not a signal. 14 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
VCYT's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-10 | +8.0% | -17.4% |
| 2023-11-09 | -2.3% | +25.5% |
| 2024-03-01 | +1.0% | -15.2% |
| 2024-05-09 | -3.8% | +9.4% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
VCYT's latest 8-K filings: 2026-07-30 (items 2.02, 9.01); 2026-06-11 (items 5.02, 5.07); 2026-05-05 (items 2.02, 9.01); 2026-03-16 (items 5.02); 2026-02-25 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.